Teleflex (TFX)
(Delayed Data from NYSE)
$239.18 USD
-0.36 (-0.15%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$239.18 USD
-0.36 (-0.15%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
Zacks News
Teleflex (TFX) Real-World Data Outcome Supports UroLift System
by Zacks Equity Research
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes
by Zacks Equity Research
Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.
Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.
Teleflex (TFX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 17.13% and 4.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Moves 3.8% Higher: Will This Strength Last?
by Zacks Equity Research
Teleflex (TFX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Add Teleflex (TFX) to Your Portfolio
by Zacks Equity Research
Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).
Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS
by Zacks Equity Research
Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.
National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes
by Zacks Equity Research
National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
by Zacks Equity Research
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark
by Zacks Equity Research
Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.
Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates
by Zacks Equity Research
Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.
Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow
by Zacks Equity Research
Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.
Masimo (MASI) Reports Study Findings Backing the SedLine
by Zacks Equity Research
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.
Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides
by Zacks Equity Research
The UroLift System remains a major contributor to Teleflex (TFX) revenues.
TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic
by Zacks Equity Research
On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.
Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View
by Zacks Equity Research
The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1
Teleflex (TFX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 17.62% and 2.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Teleflex (TFX) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.
Teleflex (TFX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 7.26% and 3.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.